Aurinia Pharmaceuticals
AUPH
260 hedge funds and large institutions have $1.1B invested in Aurinia Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 103 increasing their positions, 71 reducing their positions, and 29 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 71
41% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 29
23% more call options, than puts
Call options by funds: $7.87M | Put options by funds: $6.41M
2% more funds holding
Funds holding: 255 → 260 (+5)
0.82% more ownership
Funds ownership: 54.83% → 55.66% (+0.82%)
5% less capital invested
Capital invested by funds: $1.15B → $1.1B (-$55.9M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$21.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$13.2M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$6.83M |
| 4 |
Goldman Sachs
New York
|
+$6.24M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
+$5.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.08M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.38M |
| 3 |
Jane Street
New York
|
-$6.7M |
| 4 |
NICM
Neo Ivy Capital Management
New York
|
-$3.66M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$3.09M |
AUPH Hedge Fund Activity: Q1 2026 in Review
260 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2026, worth a combined $1.1B — down 4.9% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AUPH positions and 29 closed out — a net gain of 12 holders — while 103 added to existing stakes and 71 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $21.4M. The largest seller was Millennium Management, cutting an estimated $9.08M.
- 260 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2026, up from 255 in Q4 2025.
- Funds reported $1.1B of Aurinia Pharmaceuticals stock for Q1 2026, down 4.9% quarter-over-quarter.
- 41 funds opened new Aurinia Pharmaceuticals positions in Q1 2026 and 29 closed out, a net change of +12 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2026 was Two Sigma Investments, an estimated $21.4M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2026 was Millennium Management, an estimated $9.08M sold.
Based on aggregated 13F filings for Q1 2026.